Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its dendritc cell-based immunotherapy, AGS-004 in the treatment of HIV-infected patients receiving antiretroviral therapy (ART). The study confirmed that antiviral cytotoxic T-cell immunity can be induced in HIV infected patients without being accompanied by generalized systemic immune activation.